RB1 and colorectal carcinoma: Similar to CRC (10) and breast cancer (11), Rb protein amount and phosphorylation were suggested as markers for response to CDK4/6 inhibitors based upon proteomic data, and immune profiling revealed a spectrum of immune-cold to immune-hot tumors to potentially guide immunotherapy.